Multiple spider telangiectasias in a breast cancer patient on T-DM1 treatment

Ruiz-Rivero, Juncal; Horcajada-Reales, Celia; Tardío, Juan C.; Borbujo, J.

doi:10.1590/abd1806-4841.20187968

Cited by 5 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the literature, there are patients who developed gingival hemorrhages and epistaxis secondary to thrombocytopenia. 6,7 In our case, epistaxis was observed due to telangiectatic lesions in the nose without the development of thrombocytopenia in the 9th month of treatment. It was accompanied by telangiectatic lesions on the skin, especially on the trunk.…”

Section: Discussionmentioning

confidence: 49%

Ado-trastuzumab emtansine associated spider telangiectasia

Gürsoy

Acar

Acikalin

2022

J Oncol Pharm Pract

View full text Add to dashboard Cite

Introduction Breast cancer is the most common cancer in women. Human epidermal growth factor receptor 2 (HER2) positivity rate is 20% and generally has a poor prognosis. Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate consisting of HER2 target monoclonal antibody trastuzumab and microtubule inhibitor emtansine. The most common side effects are fatigue, diarrhea, anemia, and it is generally a safe and tolerable agent. Case report In our case, we reported our patient who developed mucosal and cutaneous telangiectasia after T-DM1 treatment and who had a complete response in metastases after skin lesions. Management and Outcome While no side effects were observed during the use of T-DM1 for HER2 positive disease, nose bleeding and spider telangiectasia on the skin developed in the 9th month of the treatment. In these lesions, which did not require any treatment, no regression was observed during T-DM1 treatment. Discussion We think that T-DM1, which was detected with a low incidence of skin toxicity in studies, may form telangiectatic lesions due to vascular dilatation through emtansine, and therefore care should be taken in the treatment of T-DM1.

show abstract

Section: Discussionmentioning

confidence: 49%

Ado-trastuzumab emtansine associated spider telangiectasia

Gürsoy

Acar

Acikalin

2022

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

“…The amplification of available treatments for breast cancer with overexpressed HER2 has considerably decreased with recurrence rates of this disease 1,2 . Trastuzumab, a monoclonal antibody developed against HER2, is administered as an adjuvant or neoadjuvant treatment, being responsible for the great advance in the prognosis of breast cancers and improving results in terms of overall survival 2,3 .…”

Section: Introductionmentioning

confidence: 99%

Multiple cutaneous telangiectasias after the use of trastuzumab: a case report

Bevilaqua

Jesus

Ferreira

et al. 2023

CBR

View full text Add to dashboard Cite

show abstract

“…Depending on the diagnosis method and the criteria for diagnosis, the prevalence rate is about 4%‐47% 4 . Women suffering from this problem usually feel high levels of distress regarding their appearance 5 . In many cases, spider nevi regress spontaneously 6 .…”

Section: Introductionmentioning

confidence: 99%

A microneedling device for the treatment of spider vein: A case report

Mohammadnejad

2020

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Spider vein is mostly seen in patients with liver disease, although the underlying problem is sometimes unknown. If spider vein appears on the face, it can affect the self‐esteem and self‐image of patients. Particularly, females are more vulnerable to these complications. Spider nevi are mostly left untreated since they are considered a cosmetic matter; in case of treatment, the procedure is costly with limited satisfaction. Therefore, this study reports the successful treatment of a spider vein case using a microneedling procedure.

show abstract

Multiple spider telangiectasias in a breast cancer patient on T-DM1 treatment

Cited by 5 publications

References 5 publications

Ado-trastuzumab emtansine associated spider telangiectasia

Ado-trastuzumab emtansine associated spider telangiectasia

Multiple cutaneous telangiectasias after the use of trastuzumab: a case report

A microneedling device for the treatment of spider vein: A case report

Contact Info

Product

Resources

About